Touchlight, founded in 2007, aims to power the genetic medicine revolution using its proprietary DNA production platform. It offers CDMO services for doggybone DNA (dbDNA) production, a critical starting material and API for use in advanced therapies, such as DNA and mRNA vaccines and cell and gene therapies. Touchlight works with over 100 biotech and pharma companies and uses its dbDNA technology for the development of its own genetic medicines. It offers rapid DNA development and manufacturing for all advanced therapy production. Touchlight is a privately owned biotech firm with state-of-the-art facilities in Hampton, UK.